#ESMO20: Regeneron, Sanofi eye another first for their PD-1 contender Libtayo with promising data for oncology niche
Regeneron and Sanofi took another step forward in the long march towards a greatly expanded market for their late-bloomer PD-1 checkpoint Libtayo.
The two occasional allies posted an objective response rate of 31% for Libtayo among 84 patients suffering from advanced cases of basal cell carcinoma at virtual ESMO. That spotlights progress for 26 patients, 5 of whom had a complete response. The data also reflect a boost in the number of responses seen from the last cut of the numbers.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 92,100+ biopharma pros reading Endpoints daily — and it's free.